about
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type.Consensus document of the Neuroendocrinology area of the Spanish Society of Endocrinology and Nutrition on management of hypopituitarism during transition.Update on prognostic factors in acromegaly: Is a risk score possible?Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 (⁎) 28 Mutation.Genetic Predictors of Response to Different Medical Therapies in Acromegaly.The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research.The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.Long-term treatment with pegvisomant for acromegaly: a 10-year experience.Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome.Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments.Long-term outcome of multimodal therapy for giant prolactinomas.Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients.Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study.The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.Erratum to: Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency.El año 2011 en NeuroendocrinologíaEscape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyCriteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensusUnmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly.Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomasPituitary stalk dysgenesis-induced hypopituitarism in adult patients: prevalence, evolution of hormone dysfunction and genetic analysis[Clinical and molecular study of five families with resistance to thyroid hormones]Pegvisomant: Balance after 10 yearsHypopituitarism after traumatic brain injuryCabergoline treatment in acromegaly: prosExpert document on management of acromegaly
P50
Q33393235-692B8B26-83B2-4937-8599-F3A69F785561Q34014158-9B654B5B-4ACC-48E4-845C-9FD00EAA00F4Q38160624-6FE86E10-607A-4D04-9828-9BCE8017D268Q38214473-70BEF046-38E8-4FD7-8D74-0399B0C0C73CQ38591741-D32D83DE-610C-4965-A698-BB531912BB27Q38759727-33FCBDD4-B98B-4D70-A10D-6DC4931B9F51Q38879404-14107E04-9DE5-413F-BA13-66A33E06D566Q38924730-C23BB007-FEB5-4707-A4D8-3B1C6991CFA4Q38964671-5968C39A-8AA5-438E-85B8-06CC6DA1F72BQ40216531-7D6AAA94-EB1B-4268-9026-A03F8FD37CDBQ43507503-AF9F9F14-ED66-4A30-AE9B-FF28AC4F8D84Q45343124-B5BD9756-6B4B-4A5D-BDC8-BD3039E0FAC6Q46101832-0E252974-510D-44D4-8CA0-3F51C4A97EA2Q46805969-0310C10B-7086-4EA0-9091-1E0BC4C6BD9AQ47669109-8407EDA7-BC36-4C14-BB07-D6A7C04DAA2BQ47936712-A97B897C-3EEB-4E71-8F67-5A1D6550A071Q51189689-D0A80D9C-A34E-4B4B-830A-A9529C3AE3E3Q51620108-B1D0838A-5D0A-42DE-96B6-A67F5BB3CE08Q51623290-0F9F80DF-5700-41D4-B1A5-3663950F5D8DQ51662568-7E3FE5C1-D773-4444-9D9E-4DA3A7EF947AQ51744127-48346B53-A87C-4015-9A6B-4F4D5DFA4180Q51803398-2FD77410-7768-4C6D-9FEB-9809B0029900Q53149941-D4CDBF4D-0601-466A-B825-BD2978C84E06Q54504621-4F5F5211-926F-4FC5-AE45-E0FCFE14A2E4Q54547137-D7CEF82E-073F-433A-ACC5-5FD79991C3E8Q60707236-508165FD-9F2E-49C5-865C-C5EBA34417D3Q62559156-3D0D9B87-D695-420D-A224-59464EADA1CAQ64045889-4AF755E2-72E6-46EC-9BF7-ACDDA0B7F487Q64964321-10D17A63-E683-486E-B658-B2C60872564CQ82526416-00AEDDE8-3354-47C0-A33E-3910215B0D5FQ83389707-785E5B39-8570-4F5D-A20F-4A258E44F7A9Q84442383-77C7260E-B234-4889-8F38-80FBB2F05BB7Q85726706-C214406B-3FFE-48E9-86DD-E3079A9356A1Q86855886-338CA056-3C88-4E24-A0F1-F952DED831B9Q87301636-CC450787-ACAF-467A-8A6B-7BDEB9656FD7Q91660667-79549CCE-7BBA-4A1F-BDCA-79B04C840927
P50
description
researcher ORCID ID = 0000-0001-8421-7394
@en
wetenschapper
@nl
name
Ignacio Bernabeu
@ast
Ignacio Bernabeu
@en
Ignacio Bernabeu
@es
Ignacio Bernabeu
@nl
type
label
Ignacio Bernabeu
@ast
Ignacio Bernabeu
@en
Ignacio Bernabeu
@es
Ignacio Bernabeu
@nl
prefLabel
Ignacio Bernabeu
@ast
Ignacio Bernabeu
@en
Ignacio Bernabeu
@es
Ignacio Bernabeu
@nl
P21
P31
P496
0000-0001-8421-7394